| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mariola Herbet, Dorota Natorska-Chomicka, Marta Ostrowska, Monika Gawrońska-Grzywacz, Magdalena Izdebska, Iwona Piątkowska-Chmiel, Agnieszka Korga, Andrzej Wróbel, Jarosław Dudk. Edaravone presents antidepressant-like activity in corticosterone model of depression in mice with possible role of Fkbp5, Comt, Adora1 and Slc6a15 genes. Toxicology and applied pharmacology. vol 380. 2020-05-19. PMID:31344373. |
paroxetine (10 mg/kg) (a selective serotonin reuptake inhibitor) and edaravone (10 mg/kg) were administered separately (ip) 30 min prior to the corticosterone injection. |
2020-05-19 |
2023-08-13 |
mouse |
| Sonika Sethi, Ravi Bhusha. Enantioselective LC analysis and determination of selective serotonin reuptake inhibitors. Biomedical chromatography : BMC. vol 34. issue 1. 2020-01-22. PMID:31652353. |
the present review article deals with the liquid chromatographic enantioseparation of chiral selective serotonin reuptake inhibitors (ssris), namely citalopram, paroxetine, sertraline and fluoxetine. |
2020-01-22 |
2023-08-13 |
human |
| Faruk Ugu. Short-Term Safety of Paroxetine Plus Low-Dose Mirtazapine During Lactation. Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine. vol 14. issue 2. 2020-01-15. PMID:30489153. |
selective serotonin reuptake inhibitors (ssris), especially sertraline and paroxetine, are first-line antidepressants in the treatment of postpartum depression in breastfeeding women as these drugs are well tolerated by most breastfed infants. |
2020-01-15 |
2023-08-13 |
Not clear |
| Magdalena Snamina, Renata Wietecha-Posłuszny, Marcin Zawadzk. Postmortem analysis of human bone marrow aspirate - Quantitative determination of SSRI and SNRI drugs. Talanta. vol 204. 2019-12-16. PMID:31357342. |
the following drugs, belonging to the group of selective serotonin (or serotonin-norepinephrine) reuptake inhibitors, were tested in this study: venlafaxine, citalopram, fluoxetine, sertraline and paroxetine. |
2019-12-16 |
2023-08-13 |
human |
| Bendtsen, Melleru. The platelet serotonin transporter in primary headaches. European journal of neurology. vol 5. issue 3. 2019-11-20. PMID:10210842. |
bmax, an index of the number of platelet 5-ht transporters, was measured in 40 patients with chronic tension-type headache, in 30 patients with migraine without aura, and in 40 healthy controls using a binding analysis with tritiated paroxetine as the ligand. |
2019-11-20 |
2023-08-12 |
Not clear |
| Silvia Mori, Sara Garbini, Matilde Caivano, Jorge Perez, Giorgio Racagn. Time-course changes in rat cerebral cortex subcellular distribution of the cyclic-AMP binding after treatment with selective serotonin reuptake inhibitors. The international journal of neuropsychopharmacology. vol 1. issue 1. 2019-11-20. PMID:11281939. |
we have extended these studies to determine the time-related effects of two selective serotonin reuptake inhibitors, fluvoxamine (15 mg/kg) and paroxetine (5 mg/kg), on the camp-binding in rat cerebral cortex, after short and long-term treatments. |
2019-11-20 |
2023-08-12 |
rat |
| Sulev Kõks, Michel Bourin, Vootele Võikar, Andres Soosaar, Eero Vasa. Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor. The international journal of neuropsychopharmacology. vol 2. issue 1. 2019-11-20. PMID:11281965. |
role of cck in anti-exploratory action of paroxetine, 5-ht reuptake inhibitor. |
2019-11-20 |
2023-08-12 |
rat |
| Sulev Kõks, Michel Bourin, Vootele Võikar, Andres Soosaar, Eero Vasa. Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor. The international journal of neuropsychopharmacology. vol 2. issue 1. 2019-11-20. PMID:11281965. |
the administration of paroxetine (0.5-8 mg/kg), a selective 5-ht reuptake inhibitor, induced a dose-dependent reduction of exploratory activity of rats in the motility test. |
2019-11-20 |
2023-08-12 |
rat |
| Steven T. Szabo, Claude de Montigny, Pierre Blie. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. The international journal of neuropsychopharmacology. vol 3. issue 1. 2019-11-20. PMID:11343573. |
sustained administration of the selective serotonin (5-ht) reuptake inhibitors (ssris) citalopram for 2, 14, and 21 d, and paroxetine for 2 and 21 d (20 and 10 mg/kg.d, respectively, s.c. using osmotic minipumps) produced a gradual decrease in spontaneous firing activity of locus coeruleus (lc) noradrenergic neurons. |
2019-11-20 |
2023-08-12 |
rat |
| Martin A. Javors, John P. Houston, Janet L. Tekell, Stephen K. Brannan, Alan Fraze. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. The international journal of neuropsychopharmacology. vol 3. issue 3. 2019-11-20. PMID:11343600. |
reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. |
2019-11-20 |
2023-08-12 |
Not clear |
| Martin A. Javors, John P. Houston, Janet L. Tekell, Stephen K. Brannan, Alan Fraze. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. The international journal of neuropsychopharmacology. vol 3. issue 3. 2019-11-20. PMID:11343600. |
to explore this issue, we carried out a study in which depressed patients were treated with either the selective serotonin reuptake inhibitor (ssri) paroxetine or the selective norepinephrine reuptake inhibitor (snri) desipramine. |
2019-11-20 |
2023-08-12 |
Not clear |
| Martin A. Javors, John P. Houston, Janet L. Tekell, Stephen K. Brannan, Alan Fraze. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. The international journal of neuropsychopharmacology. vol 3. issue 3. 2019-11-20. PMID:11343600. |
paroxetine reduced platelet 5-ht content to approx. |
2019-11-20 |
2023-08-12 |
Not clear |
| Martin A. Javors, John P. Houston, Janet L. Tekell, Stephen K. Brannan, Alan Fraze. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. The international journal of neuropsychopharmacology. vol 3. issue 3. 2019-11-20. PMID:11343600. |
the inhibition of 5-ht uptake by paroxetine appeared to be immediate and complete. |
2019-11-20 |
2023-08-12 |
Not clear |
| Martin A. Javors, John P. Houston, Janet L. Tekell, Stephen K. Brannan, Alan Fraze. Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. The international journal of neuropsychopharmacology. vol 3. issue 3. 2019-11-20. PMID:11343600. |
these results demonstrate that therapeutic concentrations of the snri desipramine as well as the ssri paroxetine inhibited serotonin uptake in platelets of depressed patients. |
2019-11-20 |
2023-08-12 |
Not clear |
| Jonathan M Powell, Emanuel Ebin, Steven Borzak, Anastasios Lymperopoulos, Charles H Henneken. Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure. Journal of cardiovascular pharmacology and therapeutics. vol 22. issue 1. 2019-11-20. PMID:27222484. |
paroxetine is a selective serotonin reuptake inhibitor which was recently shown to have the ability to directly inhibit grk2 both in vitro and in vivo. |
2019-11-20 |
2023-08-13 |
mouse |
| Robert M Nevels, Samuel T Gontkovsky, Bryman E William. Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacology bulletin. vol 46. issue 1. 2019-11-20. PMID:27738376. |
paroxetine has the highest known affinity for the serotonin transporter (0.13 nanomoles) of any currently used antidepressant. |
2019-11-20 |
2023-08-13 |
Not clear |
| P P Fon. Zebra Mussel Spawning Is Induced in Low Concentrations of Putative Serotonin Reuptake Inhibitors. The Biological bulletin. vol 194. issue 2. 2019-11-20. PMID:28570848. |
the selective serotonin reuptake inhibitors (ssris) fluvoxamine ("luvox"), fluoxetine ("prozac"), and paroxetine ("paxil") are commonly prescribed drugs for the treatment of depression in humans. |
2019-11-20 |
2023-08-13 |
Not clear |
| Sophie Billioti de Gage, Cédric Collin, Thien Le-Tri, Antoine Pariente, Bernard Bégaud, Hélène Verdoux, Rosemary Dray-Spira, Mahmoud Zurei. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS drugs. vol 32. issue 7. 2019-10-10. PMID:29959758. |
nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (snris: venlafaxine, milnacipran, duloxetine) and 'other antidepressants' (mianserin, mirtazapine, tianeptine and agomelatine), particularly in comparison with selective serotonin reuptake inhibitors (ssris: fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine, escitalopram), which are by far the most commonly prescribed antidepressants. |
2019-10-10 |
2023-08-13 |
Not clear |
| F Hieronymus, A Lisinski, S Nilsson, E Eriksso. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Molecular psychiatry. vol 23. issue 8. 2019-08-12. PMID:29155804. |
efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. |
2019-08-12 |
2023-08-13 |
human |
| Jonathan A Coleman, Eric Gouau. Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Nature structural & molecular biology. vol 25. issue 2. 2019-07-23. PMID:29379174. |
here we report x-ray structures of engineered thermostable variants of the human serotonin transporter bound to the antidepressants sertraline, fluvoxamine, and paroxetine. |
2019-07-23 |
2023-08-13 |
human |